ConductScience.org, home

Paper19084938

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.

Kogure T and 17 others. World J Gastroenterol, 2008. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. Papers, record 19084938. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19084938

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
PubMed
Journal
World J Gastroenterol
PubMed
Year
2008
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.33
iCite
Revised in PubMed
2026-01-28
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kogure TTakayuki
2Ueno YYoshiyuki
3Fukushima KKoji
4Nagasaki FFutoshi
5Kondo YYasuteru
6Inoue JJun
7Matsuda YYasunori
8Kakazu EEiji
9Yamamoto TTakeshi
10Onodera HHiroyoshi
11Miyazaki YYutaka
12Okamoto HHiromasa
13Akahane TTakehiro
14Kobayashi TTomoo
15Mano YYutaka
16Iwasaki TTakao
17Ishii MMotoyasu
18Shimosegawa TTooru

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis C, ChronicMajor topic
Interferon-alphaMajor topic
RibavirinMajor topic
Adult
Aged
Drug Therapy, Combination
Female
Genotype
Hepacivirus
Humans
Interferon alpha-2
Japan
Male
Middle Aged
Polyethylene Glycols
RNA, Viral
Recombinant Proteins
Treatment Outcome
Viral Load

Source PubMed

Download CSV of topics

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115044832Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.Intervirology2004https://conductscience.org/library/papers/15044832PubMed
215880320Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.Clin Gastroenterol Hepatol2005https://conductscience.org/library/papers/15880320PubMed
317714473Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C.Hepatol Res2008https://conductscience.org/library/papers/17714473PubMed
415508082Hepatocellular carcinoma: recent trends in Japan.Gastroenterology2004https://conductscience.org/library/papers/15508082PubMed
512640530Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.J Gastroenterol2003https://conductscience.org/library/papers/12640530PubMed
612395340Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.Hepatology2002https://conductscience.org/library/papers/12395340PubMed
712761728Side effects of therapy for chronic hepatitis C.Gastroenterology2003https://conductscience.org/library/papers/12761728PubMed
811583749Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001https://conductscience.org/library/papers/11583749PubMed
916871572Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race.Hepatology2006https://conductscience.org/library/papers/16871572PubMed
1017728547Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.Intervirology2007https://conductscience.org/library/papers/17728547PubMed
1112360468Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology2002https://conductscience.org/library/papers/12360468PubMed
1217657816Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.Hepatology2007https://conductscience.org/library/papers/17657816PubMed
1312195046Epidemiology and clinical aspects on hepatitis C.Jpn J Infect Dis2002https://conductscience.org/library/papers/12195046PubMed
1412939591Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology2003https://conductscience.org/library/papers/12939591PubMed
1517854035Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.J Med Virol2007https://conductscience.org/library/papers/17854035PubMed
1615057741Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.Gastroenterology2004https://conductscience.org/library/papers/15057741PubMed
1715163776Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.N Engl J Med2004https://conductscience.org/library/papers/15163776PubMed
189819446Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med1998https://conductscience.org/library/papers/9819446PubMed
1917877503Epidemiology of hepatocellular carcinoma in Japan.Hepatol Res2007https://conductscience.org/library/papers/17877503PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
25755575Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.J Clin Exp Hepatol2014https://conductscience.org/library/papers/25755575PubMed
24812506Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Int J Nanomedicine2014https://conductscience.org/library/papers/24812506PubMed
23543311Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.J Gastroenterol2014https://conductscience.org/library/papers/23543311PubMed
21706207Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.Dig Dis Sci2011https://conductscience.org/library/papers/21706207PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19084938

GET https://conductscience.org/api/papers/v1/19084938/authors